The EU-supported EuroFlow Consortium aimed at innovation and standardization of
immunophenotyping for diagnosis and classification of hematological malignancies by introducing 8…

In recent years, several studies on large series of multiple myeloma (MM) patients have
demonstrated the clinical utility of flow cytometry monitoring of minimal residual disease (flow‐…

Most consensus leukemia & lymphoma antibody panels consist of lists of markers based on
expert opinions, but they have not been validated. Here we present the validated EuroFlow 8…

Background A diagnosis of chronic lymphocytic leukemia (CLL) requires a count of over
5000 circulating CLL-phenotype cells per cubic millimeter. Asymptomatic persons with fewer …

The European Myeloma Network (EMN) organized two flow cytometry workshops. The first
aimed to identify specific indications for flow cytometry in patients with monoclonal …

… de Tute, Gordon Cook, and Roger G. Owen, St … van de Velde HJ, Liu X, Chen G, et al:
Complete response correlates with long-term survival and progression-free survival in high-dose …

Poulter and colleagues describe a series from the United Kingdom of 10 male patients with
VEXAS syndrome, including 2 with novel genetic changes affecting methionine 41 of E1.

The detection of minimal residual disease (MRD) in myeloma using a 0.01% threshold (10 −4
) after treatment is an independent predictor of progression-free survival (PFS), but not …

Background Major heterogeneity between laboratories in flow cytometry (FC) minimal residual
disease (MRD) testing in multiple myeloma (MM) must be overcome. Cytometry societies …

… The authors’ full names, academic degrees, and affiliations are listed in the Appendix. Dr. …
Myelodysplastic syndrome or acute myeloid leukemia developed in 1 patient in the ibrutinib–…